• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Throat Cancer - Pipeline Review, H2 2012 Product Image

Throat Cancer - Pipeline Review, H2 2012

  • Published: October 2012
  • 232 pages
  • Global Markets Direct

Throat Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Throat Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Throat Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Throat Cancer. Throat Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Throat Cancer.
- A review of the Throat Cancer products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Throat Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Throat Cancer 10
Throat Cancer Therapeutics under Development by Companies 12
Throat Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Throat Cancer Therapeutics – Products under Development by Companies 24
Throat Cancer Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Throat Cancer Therapeutics Development 31
F. Hoffmann-La Roche Ltd. 31
Sanofi-Aventis 32
YM BioSciences Inc. 33
Cyclacel Pharmaceuticals Inc. 34
Advaxis, Inc. 35
Prima BioMed Limited 36
Jiangsu Hengrui Medicine Co., Ltd. 37
Biotech Pharmaceuticals Co., Ltd. 38
Throat Cancer – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
seliciclib - Drug Profile 45
ADXS-HPV - Drug Profile 47
Cisplatin + Radiation Therapy - Drug Profile 49
HPPH - Drug Profile 50
Vorinostat + Capecitabine - Drug Profile 52
Cetuximab + Cisplatin - Drug Profile 54
Cisplatinum + Radiotherapy - Drug Profile 56
Xeloda + Oxaliplatin - Drug Profile 58
5-Fluorouracil + Hydroxyurea + Bevacizumab + Radiation Therapy - Drug Profile 60
cisplatin - Drug Profile 62
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile 65
EBNA-1 - Drug Profile 66
Cisplatin + Radiation Therapy1 - Drug Profile 67
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 68
Cisplatin + Xeloda + Radiation Therapy - Drug Profile 70
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 72
pazopanib hydrochloride - Drug Profile 74
Gemcitabine + Cisplatinn - Drug Profile 75
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 76
Carboplatin + Paclitaxel - Drug Profile 78
Taxotere + Cisplatin + Radiation Therapy - Drug Profile 80
Fludarabine + Radiation Therapy - Drug Profile 82
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 83
Radiation Therapy + Cetuximab - Drug Profile 84
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 86
Docetaxel + Cisplatin - Drug Profile 88
Bevacizumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 90
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 92
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 94
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 96
Docetaxel + Cisplatin + Fluorouracil - Drug Profile 98
celecoxib - Drug Profile 100
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 101
nimotuzumab - Drug Profile 103
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile 105
Sorafenib + Cisplatin + 5-Fluorouracil - Drug Profile 106
Gemcitabine + Carboplatin - Drug Profile 108
bortezomib - Drug Profile 110
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 111
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 113
temoporfin - Drug Profile 114
Docetaxel + Cisplatin + 5-Fluorouracil + Radiotherapy - Drug Profile 115
TS-1 + Nedaplatin + Radiation Therapy - Drug Profile 117
Cisplatin + 5-Fluorouracil + Celecoxib + Radiation Therapy - Drug Profile 118
S-1 + Radiation Therapy - Drug Profile 120
Cisplatin + Radiation Therapy - Drug Profile 121
S-1 + Radiation Therapy - Drug Profile 122
minocycline - Drug Profile 124
Docetaxel + 5-Fluorouracil + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 125
Mitomycin C + Epirubicin + Cisplatin + 5-Fluorouracil + Leucovorin - Drug Profile 127
Docetaxel + Radiation Therapy - Drug Profile 129
Carbogen + Nicotinamide + Radiotherapy - Drug Profile 130
Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile 131
Cisplatin + 5FU + Taxotere - Drug Profile 133
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile 135
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 137
Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile 139
Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile 141
Cisplatin + Cetuximab + 5-Fluorouracil + Taxotere + Radiation Therapy - Drug Profile 142
Interleukin + NK Cells - Drug Profile 144
Cetuximab + Docetaxel + Cisplatin + 5-FU - Drug Profile 145
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 147
Bevacizumab + Cisplatin + Fluorouracil - Drug Profile 148
Cetuximab + Cisplatin + Docetaxel + 5-FU - Drug Profile 150
Cetuximab + Cisplatin + Radiation Therapyy - Drug Profile 152
pemetrexed disodium - Drug Profile 154
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 155
Cisplatin - Drug Profile 157
Adriamycin + Lomustine - Drug Profile 158
Erbitux + Docetaxel + Cisplatin - Drug Profile 159
Amifostine + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 161
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 163
Lapatinib Ditosylate + Capecitabine - Drug Profile 164
Taxotere + Cisplatin + 5-FU - Drug Profile 166
Cisplatin + Radiation Therapy - Drug Profile 168
Erbitux + Radiation Therapy - Drug Profile 169
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 170
Docetaxel + Cisplatin + 5-Fluorouracil + Erbitux + Radiation Therapy - Drug Profile 172
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile 174
Nedaplatin + Radiation Therapy - Drug Profile 176
Modified Vaccinia Ankara - Drug Profile 177
axitinib - Drug Profile 178
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 179
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 181
Sunitinib + Cisplatin + Gemcitabine - Drug Profile 183
Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 185
Nimotuzumab + Cisplatin - Drug Profile 187
LBH589 + RAD001 - Drug Profile 188
S-1 + Radiation Therapy - Drug Profile 189
MK-2206 - Drug Profile 190
Cisplatin + Radiation Therapy - Drug Profile 191
famitinib - Drug Profile 192
S-1 + Oxaliplatin - Drug Profile 193
MK-2206 - Drug Profile 194
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile 195
Gemcitabine + Valproic acid + Valganciclovir - Drug Profile 197
Famitinib + Cisplatin + Radiation Therapy - Drug Profile 199
Nedaplatin + Radiation Therapy - Drug Profile 201
Celecoxib + Radiation Therapy - Drug Profile 202
Cripto-1 Monoclonal Antibody - Drug Profile 203
AT-101 + Docetaxel + Cisplatin - Drug Profile 204
Gemcitabine + Cisplatin + Cytokine induced killer cells - Drug Profile 205
Throat Cancer Therapeutics – Drug Profile Updates 206
Throat Cancer Therapeutics – Discontinued Products 212
Throat Cancer Therapeutics - Dormant Products 214
Throat Cancer – Product Development Milestones 219
Featured News & Press Releases 219
Appendix 224
Methodology 224
Coverage 224
Secondary Research 224
Primary Research 224
Expert Panel Validation 224
Contact Us 225
Disclaimer 225

List of Tables
Number of Products Under Development for Throat Cancer, H2 2012 17
Products under Development for Throat Cancer – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 26
Comparative Analysis by Late Stage Development, H2 2012 27
Comparative Analysis by Mid Clinical Stage Development, H2 2012 28
Comparative Analysis by Early Clinical Stage Development, H2 2012 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 30
Products under Development by Companies, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 37
F. Hoffmann-La Roche Ltd., H2 2012 38
Sanofi-Aventis, H2 2012 39
YM BioSciences Inc., H2 2012 40
Cyclacel Pharmaceuticals Inc., H2 2012 41
Advaxis, Inc., H2 2012 42
Prima BioMed Limited, H2 2012 43
Jiangsu Hengrui Medicine Co., Ltd., H2 2012 44
Biotech Pharmaceuticals Co., Ltd., H2 2012 45
Assessment by Monotherapy Products, H2 2012 46
Assessment by Combination Products, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 51
Throat Cancer Therapeutics – Drug Profile Updates 213
Throat Cancer Therapeutics – Discontinued Products 219
Throat Cancer Therapeutics – Discontinued Products (Contd..1) 220
Throat Cancer Therapeutics – Dormant Products 221
Throat Cancer Therapeutics – Dormant Products (Contd..1) 222
Throat Cancer Therapeutics – Dormant Products (Contd..2) 223
Throat Cancer Therapeutics – Dormant Products (Contd..3) 224
Throat Cancer Therapeutics – Dormant Products (Contd..4) 225

List of Figures
Number of Products under Development for Throat Cancer, H2 2012 17
Products under Development for Throat Cancer – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 27
Mid Clinical Stage Products, H2 2012 28
Early Clinical Stage Products, H2 2012 29
Discovery and Pre-Clinical Stage Products, H2 2012 30
Assessment by Monotherapy Products, H2 2012 46
Assessment by Combination Products, H2 2012 47
Assessment by Route of Administration, H2 2012 48
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Molecule Type, H2 2012 50
Assessment by Stage and Molecule Type, H2 2012 51

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos